Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease

Free Radical Biology and Medicine

Volumn 101, Issue , 2016, Pages 393-400

  Doria, Margaux ^a   Maugest, Lucie ^a,b   Moreau, Thibault ^a,b   Lizard, Gérard ^a   Vejux, Anne ^a  

^a Faculté des Sciences Gabriel   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Cholesterol; Oxysterol; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CHOLESTEROL; LIPID; OXYSTEROL; PROTEIN AGGREGATE;

BRAIN; CELL DEATH; HUMAN; INFLAMMATION; LIPID METABOLISM; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; CHEMISTRY; DOPAMINERGIC NERVE CELL; METABOLISM; NERVE ENDING; OXIDATION REDUCTION REACTION; PATHOLOGY; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; CELL DEATH; CHOLESTEROL; DOPAMINERGIC NEURONS; HUMANS; OXIDATION-REDUCTION; OXYSTEROLS; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; PROTEIN AGGREGATES; SUBSTANTIA NIGRA;

EID: 84994553209     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.10.008     Document Type: Review

References (83)

1. [1] Lutjohann, D., Papassotiropoulos, A., Bjorkhem, I., Locatelli, S., Bagli, M., Oehring, R.D., Schlegel, U., Jessen, F., Rao, M.L., von Bergmann, K., Heun, R., Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41:2 (2000), 195–198.
2. [2] Boenzi, S., Deodato, F., Taurisano, R., Goffredo, B.M., Rizzo, C., Dionisi-Vici, C., Evaluation of plasma cholestane-3beta,5alpha,6beta-triol and 7-ketocholesterol in inherited disorders related to cholesterol metabolism. J. Lipid Res. 57:3 (2016), 361–367.
3. [3] Zarrouk, A., Riedinger, J.M., Ahmed, S.H., Hammami, S., Chaabane, W., Debbabi, M., Ben Ammou, S., Rouaud, O., Frih, M., Lizard, G., Hammami, M., Fatty acid profiles in demented patients: identification of hexacosanoic acid (C26:0) as a blood lipid biomarker of dementia. J. Alzheimer's Dis. 44:4 (2015), 1349–1359.
4. [4] Astarita, G., Jung, K.M., Vasilevko, V., Dipatrizio, N.V., Martin, S.K., Cribbs, D.H., Head, E., Cotman, C.W., Piomelli, D., Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. PLoS One, 6(10), 2011, e24777.
5. [5] Kou, J., Kovacs, G.G., Hoftberger, R., Kulik, W., Brodde, A., Forss-Petter, S., Honigschnabl, S., Gleiss, A., Brugger, B., Wanders, R., Just, W., Budka, H., Jungwirth, S., Fischer, P., Berger, J., Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol. 122:3 (2011), 271–283.
6. [6] Zarrouk, A., Vejux, A., Mackrill, J., O'Callaghan, Y., Hammami, M., O'Brien, N., Lizard, G., Involvement of oxysterols in age-related diseases and ageing processes. Ageing Res. Rev. 18 (2014), 148–162.
7. [7] Zarrouk, A., Hammami, M., Moreau, T., Lizard, G., Accumulation of 24S-hydroxycholesterol in neuronal SK-N-BE cells treated with hexacosanoic acid (C26:0): argument in favor of 24S-hydroxycholesterol as a potential biomarker of neurolipotoxicity. Rev. Neurol. 171:2 (2015), 125–129.
8. [8] Jiang, X., Sidhu, R., Porter, F.D., Yanjanin, N.M., Speak, A.O., te Vruchte, D.T., Platt, F.M., Fujiwara, H., Scherrer, D.E., Zhang, J., Dietzen, D.J., Schaffer, J.E., Ory, D.S., A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma. J. Lipid Res. 52:7 (2011), 1435–1445.
9. [9] van de Kraats, C., Killestein, J., Popescu, V., Rijkers, E., Vrenken, H., Lutjohann, D., Barkhof, F., Polman, C.H., Teunissen, C.E., Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. Mult. Scler. 20:4 (2014), 412–417.
10. [10] Nury, T., Zarrouk, A., Ragot, K., Debbabi, M., Riedinger, J.M., Vejux, A., Aubourg, P., Lizard, G., 7-Ketocholesterol is increased in the plasma of X-ALD patients and induces peroxisomal modifications in microglial cells: Potential roles of 7-ketocholesterol in the pathophysiology of X-ALD. J. Steroid Biochem. Mol. Biol., 2016.
11. [11] Martin, M.G., Pfrieger, F., Dotti, C.G., Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep. 15:10 (2014), 1036–1052.
12. [12] Li, Z., Zhang, J., Sun, H., Increased plasma levels of phospholipid in Parkinson's disease with mild cognitive impairment. J. Clin. Neurosci., 2015.
13. [13] Dickson, D.W., Braak, H., Duda, J.E., Duyckaerts, C., Gasser, T., Halliday, G.M., Hardy, J., Leverenz, J.B., Del Tredici, K., Wszolek, Z.K., Litvan, I., Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 8:12 (2009), 1150–1157.
14. [14] Dexter, D.T., Jenner, P., Parkinson disease: from pathology to molecular disease mechanisms. Free Radic. Biol. Med. 62 (2013), 132–144.
15. [15] Hughes, A.J., Daniel, S.E., Ben-Shlomo, Y., Lees, A.J., The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:Pt 4 (2002), 861–870.
16. [16] Fearnley, J.M., Lees, A.J., Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114:Pt 5 (1991), 2283–2301.
17. [17] O'Sullivan, S.S., Williams, D.R., Gallagher, D.A., Massey, L.A., Silveira-Moriyama, L., Lees, A.J., Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov. Disord. 23:1 (2008), 101–106.
18. [18] Delenclos, M., Jones, D.R., McLean, P.J., Uitti, R.J., Biomarkers in Parkinson's disease: advances and strategies. Parkinsonism Relat. Disord., 2015.
19. [19] Imaizumi, Y., Okada, Y., Akamatsu, W., Koike, M., Kuzumaki, N., Hayakawa, H., Nihira, T., Kobayashi, T., Ohyama, M., Sato, S., Takanashi, M., Funayama, M., Hirayama, A., Soga, T., Hishiki, T., Suematsu, M., Yagi, T., Ito, D., Kosakai, A., Hayashi, K., Shouji, M., Nakanishi, A., Suzuki, N., Mizuno, Y., Mizushima, N., Amagai, M., Uchiyama, Y., Mochizuki, H., Hattori, N., Okano, H., Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain, 5, 2012, 35.
20. [20] Fukae, J., Mizuno, Y., Hattori, N., Mitochondrial dysfunction in Parkinson's disease. Mitochondrion 7:1–2 (2007), 58–62.
21. [21] Perier, C., Tieu, K., Guegan, C., Caspersen, C., Jackson-Lewis, V., Carelli, V., Martinuzzi, A., Hirano, M., Przedborski, S., Vila, M., Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc. Natl. Acad. Sci. USA 102:52 (2005), 19126–19131.
22. [22] Jenner, P., Oxidative stress in Parkinson's disease. Ann. Neurol. 53:Suppl 3 (2003), S26–S36 discussion S36-8.
23. [23] Chiurchiu, V., Orlacchio, A., Maccarrone, M., Is modulation of oxidative stress an answer? the state of the art of redox therapeutic actions in neurodegenerative diseases. Oxid. Med. Cell. Longev., 2016 (2016) 7909380.
24. [24] Sutachan, J.J., Casas, Z., Albarracin, S.L., Stab, B.R. 2nd, Samudio, I., Gonzalez, J., Morales, L., Barreto, G.E., Cellular and molecular mechanisms of antioxidants in Parkinson's disease. Nutr. Neurosci. 15:3 (2012), 120–126.
25. [25] Seidl, S.E., Santiago, J.A., Bilyk, H., Potashkin, J.A., The emerging role of nutrition in Parkinson's disease. Front. Aging Neurosci., 6, 2014, 36.
26. [26] Li, Z., Wang, P., Yu, Z., Cong, Y., Sun, H., Zhang, J., Zhang, J., Sun, C., Zhang, Y., Ju, X., The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease. Eur. Neurol. 73:3-4 (2015), 205–211.
27. [27] McNaught, K.S., Jenner, P., Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:3 (2001), 191–194.
28. [28] Olanow, C.W., McNaught, K.S., Ubiquitin-proteasome system and Parkinson's disease. Mov. Disord. 21:11 (2006), 1806–1823.
29. [29] McNaught, K.S., Belizaire, R., Isacson, O., Jenner, P., Olanow, C.W., Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179:1 (2003), 38–46.
30. [30] McNaught, K.S., Belizaire, R., Jenner, P., Olanow, C.W., Isacson, O., Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326:3 (2002), 155–158.
31. [31] Vejux, A., Lizard, G., Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. Mol. Asp. Med. 30:3 (2009), 153–170.
32. [32] Paul, R., Choudhury, A., Borah, A., Cholesterol – a putative endogenous contributor towards Parkinson's disease. Neurochem. Int. 90 (2015), 125–133.
33. [33] Guo, X., Song, W., Chen, K., Chen, X., Zheng, Z., Cao, B., Huang, R., Zhao, B., Wu, Y., Shang, H.F., The serum lipid profile of Parkinson's disease patients: a study from China. Int. J. Neurosci., 2014.
34. [34] Tan, L.C., Methawasin, K., Tan, E.K., Tan, J.H., Au, W.L., Yuan, J.M., Koh, W.P., Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese health study. J. Neurol. Neurosurg. Psychiatry, 2015.
35. [35] Gudala, K., Bansal, D., Muthyala, H., Role of serum cholesterol in Parkinson's disease: a meta-analysis of evidence. J. Parkinson's Dis. 3:3 (2013), 363–370.
36. [36] Cheng, D., Jenner, A.M., Shui, G., Cheong, W.F., Mitchell, T.W., Nealon, J.R., Kim, W.S., McCann, H., Wenk, M.R., Halliday, G.M., Garner, B., Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One, 6(2), 2011, e17299.
37. [37] Bar-On, P., Crews, L., Koob, A.O., Mizuno, H., Adame, A., Spencer, B., Masliah, E., Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J. Neurochem. 105:5 (2008), 1656–1667.
38. [38] Wolozin, B., Wang, S.W., Li, N.C., Lee, A., Lee, T.A., Kazis, L.E., Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med., 5, 2007, 20.
39. [39] Koob, A.O., Ubhi, K., Paulsson, J.F., Kelly, J., Rockenstein, E., Mante, M., Adame, A., Masliah, E., Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp. Neurol. 221:2 (2010), 267–274.
40. [40] Bar-On, P., Rockenstein, E., Adame, A., Ho, G., Hashimoto, M., Masliah, E., Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy. J. Neurochem. 98:4 (2006), 1032–1045.
41. [41] Fantini, J., Carlus, D., Yahi, N., The fusogenic tilted peptide (67-78) of alpha-synuclein is a cholesterol binding domain. Biochim. Biophys. Acta 1808:10 (2011), 2343–2351.
42. [42] Boselli, E., Velazco, V., Caboni, M.F., Lercker, G., Pressurized liquid extraction of lipids for the determination of oxysterols in egg-containing food. J. Chromatogr. A 917:1-2 (2001), 239–244.
43. [43] Przygonski, K., Jelen, H., Wasowicz, E., Determination of cholesterol oxidation products in milk powder and infant formulas by gas chromatography and mass spectrometry. Nahrung 44:2 (2000), 122–125.
44. [44] Leonarduzzi, G., Sottero, B., Poli, G., Oxidized products of cholesterol: dietary and metabolic origin, and proatherosclerotic effects (review). J. Nutr. Biochem. 13:12 (2002), 700–710.
45. [45] Yan, P.S., Cholesterol oxidation products. Their occurrence and detection in our foodstuffs. Adv. Exp. Med. Biol 459 (1999), 79–98.
46. [46] Maria Teresa, R.-E., Giovanni, L., Cholesterol Oxidation Mechanisms, Cholesterol and Phytosterol Oxidation Products. 2002, AOCS Publishing, 1–25.
47. [47] Patel, R.P., Diczfalusy, U., Dzeletovic, S., Wilson, M.T., Darley-Usmar, V.M., Formation of oxysterols during oxidation of low density lipoprotein by peroxynitrite, myoglobin, and copper. J. Lipid Res. 37:11 (1996), 2361–2371.
48. [48] Vejux, A., Samadi, M., Lizard, G., Contribution of cholesterol and oxysterols in the physiopathology of cataract: implication for the development of pharmacological treatments. J. Ophthalmol., 2011, 2011, 471947.
49. [49] Iuliano, L., Pathways of cholesterol oxidation via non-enzymatic mechanisms. Chem. Phys. Lipids 164:6 (2011), 457–468.
50. [50] Kulig, W., Cwiklik, L., Jurkiewicz, P., Rog, T., Vattulainen, I., Cholesterol oxidation products and their biological importance. Chem. Phys. Lipids, 2016.
51. [51] Lutjohann, D., Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol. Scand. Suppl. 185 (2006), 33–42.
52. [52] Leoni, V., Masterman, T., Patel, P., Meaney, S., Diczfalusy, U., Bjorkhem, I., Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J. Lipid Res. 44:4 (2003), 793–799.
53. [53] Bjorkhem, I., Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 260:6 (2006), 493–508.
54. [54] Iuliano, L., Crick, P.J., Zerbinati, C., Tritapepe, L., Abdel-Khalik, J., Poirot, M., Wang, Y., Griffiths, W.J., Cholesterol metabolites exported from human brain. Steroids (Pt B) 99 (2015), 189–193.
55. [55] Nury, T., Zarrouk, A., Mackrill, J.J., Samadi, M., Durand, P., Riedinger, J.M., Doria, M., Vejux, A., Limagne, E., Delmas, D., Prost, M., Moreau, T., Hammami, M., Delage-Mourroux, R., O'Brien, N.M., Lizard, G., Induction of oxiapoptophagy on 158N murine oligodendrocytes treated by 7-ketocholesterol-, 7beta-hydroxycholesterol-, or 24(S)-hydroxycholesterol: Protective effects of alpha-tocopherol and docosahexaenoic acid (DHA; C22:6 n-3). Steroids (Pt B) 99 (2015), 194–203.
56. [56] Gamba, P., Leonarduzzi, G., Tamagno, E., Guglielmotto, M., Testa, G., Sottero, B., Gargiulo, S., Biasi, F., Mauro, A., Vina, J., Poli, G., Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-beta in amplifying neuronal damage in Alzheimer's disease: three partners in crime. Aging Cell 10:3 (2011), 403–417.
57. [57] Heverin, M., Meaney, S., Lutjohann, D., Diczfalusy, U., Wahren, J., Bjorkhem, I., Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 46:5 (2005), 1047–1052.
58. [58] Stapleton, G., Steel, M., Richardson, M., Mason, J.O., Rose, K.A., Morris, R.G., Lathe, R., A novel cytochrome P450 expressed primarily in brain. J. Biol. Chem. 270:50 (1995), 29739–29745.
59. [59] Meaney, S., Heverin, M., Panzenboeck, U., Ekstrom, L., Axelsson, M., Andersson, U., Diczfalusy, U., Pikuleva, I., Wahren, J., Sattler, W., Bjorkhem, I., Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J. Lipid Res. 48:4 (2007), 944–951.
60. [60] Saeed, A., Floris, F., Andersson, U., Pikuleva, I., Lovgren-Sandblom, A., Bjerke, M., Paucar, M., Wallin, A., Svenningsson, P., Bjorkhem, I., 7alpha-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid reflects the integrity of the blood-brain barrier. J. Lipid Res. 55:2 (2014), 313–318.
61. [61] Crick, P.J., William Bentley, T., Abdel-Khalik, J., Matthews, I., Clayton, P.T., Morris, A.A., Bigger, B.W., Zerbinati, C., Tritapepe, L., Iuliano, L., Wang, Y., Griffiths, W.J., Quantitative charge-tags for sterol and oxysterol analysis. Clin. Chem. 61:2 (2015), 400–411.
62. [62] Bretillon, L., Siden, A., Wahlund, L.O., Lutjohann, D., Minthon, L., Crisby, M., Hillert, J., Groth, C.G., Diczfalusy, U., Bjorkhem, I., Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci. Lett. 293:2 (2000), 87–90.
63. [63] Leoni, V., Oxysterols as markers of neurological disease–a review. Scand. J. Clin. Lab. Investig. 69:1 (2009), 22–25.
64. [64] Bosco, D.A., Fowler, D.M., Zhang, Q., Nieva, J., Powers, E.T., Wentworth, P. Jr., Lerner, R.A., Kelly, J.W., Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat. Chem. Biol. 2:5 (2006), 249–253.
65. [65] Rantham Prabhakara, J.P., Feist, G., Thomasson, S., Thompson, A., Schommer, E., Ghribi, O., Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells. J. Neurochem. 107:6 (2008), 1722–1729.
66. [66] Cheng, D., Kim, W.S., Garner, B., Regulation of alpha-synuclein expression by liver X receptor ligands in vitro. Neuroreport 19:17 (2008), 1685–1689.
67. [67] Kolsch, H., Ludwig, M., Lutjohann, D., Rao, M.L., Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J. Neural Transm. 108:4 (2001), 475–488.
68. [68] Marwarha, G., Rhen, T., Schommer, T., Ghribi, O., The oxysterol 27-hydroxycholesterol regulates alpha-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors–relevance to Parkinson's disease. J. Neurochem. 119:5 (2011), 1119–1136.
69. [69] DuSell, C.D., Umetani, M., Shaul, P.W., Mangelsdorf, D.J., McDonnell, D.P., 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol. Endocrinol. 22:1 (2008), 65–77.
70. [70] Umetani, M., Domoto, H., Gormley, A.K., Yuhanna, I.S., Cummins, C.L., Javitt, N.B., Korach, K.S., Shaul, P.W., Mangelsdorf, D.J., 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13:10 (2007), 1185–1192.
71. [71] Bjorkhem, I., Lovgren-Sandblom, A., Leoni, V., Meaney, S., Brodin, L., Salveson, L., Winge, K., Palhagen, S., Svenningsson, P., Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci. Lett. 555 (2013), 102–105.
72. [72] Marwarha, G., Ghribi, O., Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap?. Exp. Gerontol. 68 (2014), 13–18.
73. [73] Ong, W.Y., Goh, E.W., Lu, X.R., Farooqui, A.A., Patel, S.C., Halliwell, B., Increase in cholesterol and cholesterol oxidation products, and role of cholesterol oxidation products in kainate-induced neuronal injury. Brain Pathol. 13:3 (2003), 250–262.
74. [74] Lang, E., Lang, F., Triggers, inhibitors, mechanisms, and significance of eryptosis: the suicidal erythrocyte death. BioMed Res. Int. 2015, 2015, 513518.
75. [75] Pretorius, E., Swanepoel, A.C., Buys, A.V., Vermeulen, N., Duim, W., Kell, D.B., Eryptosis as a marker of Parkinson's disease. Aging Dis. 6:10 (2014), 788–819.
76. [76] Tesoriere, L., Attanzio, A., Allegra, M., Cilla, A., Gentile, C., Livrea, M.A., Oxysterol mixture in hypercholesterolemia-relevant proportion causes oxidative stress-dependent eryptosis. Cell. Physiol. Biochem. 34:4 (2014), 1075–1089.
77. [77] Fernandes, H.J., Hartfield, E.M., Christian, H.C., Emmanoulidou, E., Zheng, Y., Booth, H., Bogetofte, H., Lang, C., Ryan, B.J., Sardi, S.P., Badger, J., Vowles, J., Evetts, S., Tofaris, G.K., Vekrellis, K., Talbot, K., Hu, M.T., James, W., Cowley, S.A., Wade-Martins, R., ER stress and autophagic perturbations lead to elevated extracellular alpha-synuclein in GBA-N370S Parkinson's iPSC-derived dopamine neurons. Stem Cell Rep. 6:3 (2016), 342–356.
78. [78] Nury, T., Zarrouk, A., Vejux, A., Doria, M., Riedinger, J.M., Delage-Mourroux, R., G. Lizard, Induction of oxiapoptophagy, a mixed mode of cell death associated with oxidative stress, apoptosis and autophagy, on 7-ketocholesterol-treated 158N murine oligodendrocytes: impairment by alpha-tocopherol. Biochem. Biophys. Res. Commun., 2013.
79. [79] Sudo, R., Sato, F., Azechi, T., Wachi, H., 7-Ketocholesterol-induced lysosomal dysfunction exacerbates vascular smooth muscle cell calcification via oxidative stress. Genes Cells 20:12 (2015), 982–991.
80. [80] Marengo, B., Bellora, F., Ricciarelli, R., Ciucis, C. De, Furfaro, A., Leardi, R., Colla, R., Pacini, D., Traverso, N., Moretta, A., Pronzato, M.A., Bottino, C., Domenicotti, C., Oxysterol mixture and, in particular, 27-hydroxycholesterol drive M2 polarization of human macrophages. BioFactors 42:1 (2016), 80–92.
81. [81] Kim, S.M., Lee, C.W., Kim, B.Y., Jung, Y.S., Eo, S.K., Park, Y.C., Kim, K., 27-Oxygenated cholesterol induces expression of CXCL8 in macrophages via NF-kappaB and CD88. Biochem. Biophys. Res. Commun. 463:4 (2015), 1152–1158.
82. [82] Kim, S.M., Lee, S.A., Kim, B.Y., Bae, S.S., Eo, S.K., Kim, K., 27-Hydroxycholesterol induces recruitment of monocytic cells by enhancing CCL2 production. Biochem. Biophys. Res. Commun. 442:3-4 (2013), 159–164.
83. [83] Vurusaner, B., Gamba, P., Gargiulo, S., Testa, G., Staurenghi, E., Leonarduzzi, G., Poli, G., Basaga, H., Nrf2 antioxidant defense is involved in survival signaling elicited by 27-hydroxycholesterol in human promonocytic cells. Free Radic. Biol. Med. 91 (2016), 93–104.